Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sonsoles Velázquez is active.

Publication


Featured researches published by Sonsoles Velázquez.


Antiviral Chemistry & Chemotherapy | 1998

Regiospecific Synthesis and Anti-Human Immunodeficiency Virus Activity of Novel 5-Substituted N-Alkylcarbamoyl and N,N-Dialkyl Carbamoyl 1,2,3-Triazole-TSAO Analogues

Sonsoles Velázquez; Rosa Alvarez; Carlos Pérez; Federico Gago; E. De Clercq; Jan Balzarini; M J Camarasa

Several 5-N-alkyl and 5-N,N-dialkylcarbamoyl substituted analogues of the anti-human immunodeficiency virus (HIV) type 1 lead compound[1-[2‘,5’-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-5-(N,N-dimethylcarbamoyl)-1,2,3-triazole]-3‘-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) have been prepared and evaluated as inhibitors of HIV-1 replication. A new regiospecific synthetic procedure is described. The compounds were prepared by cycloaddition of the appropriate glycosylazide to 2-oxo-alkylidentriphenyl-phosphoranes, followed by treatment with primary or secondary amines, to yield, exclusively, 5-substituted 1,2,3-triazole-TSAO analogues. Several 5-substituted 1,2,3-triazole-TSAO derivatives proved to be potent inhibitors of HIV-1 replication with higher antiviral selectivity than that of the parent TSAO prototype.


Current Topics in Medicinal Chemistry | 2004

TSAO compounds: The comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase

María-José Camarasa; Ana San-Félix; Sonsoles Velázquez; María-Jesús Pérez-Pérez; Federico Gago; Jan Balzarini

Emergence of drug-resistant viral strains is one of the major milestones and the main cause for the failure of antiretroviral therapy. Combination of different anti-HIV agents has become the standard clinical practice to keep the viral load at low or even undetectable levels and to prevent emergence of virus-drug resistance. Among the human immunodeficiency virus (HIV) reverse transcriptase (RT) inhibitors, the so called nonnucleoside RT inhibitors (NNRTIs) have gained a definitive place in the treatment of HIV infections in combination with nucleoside analogue RT inhibitors (NRTIs) and HIV protease inhibitors (PIs). The virus can be markedly suppressed for a relatively long period of time when exposed to multiple drug combination therapy (highly active antiretroviral therapy, HAART). TSAO derivatives are a peculiar group of highly functionalized nucleosides that belong to the so-called nonnucleoside RT inhibitors (NNRTIs). They exert their unique selectivity for HIV-1 through a specific interaction with the p51 subunit of HIV-1 RT. They are the first small molecules that seem to interfere with the dimerization process of the enzyme. This review covers the work carried out with this unique class of specific inhibitors of HIV-1 reverse transcriptase, including structure activity relationship studies (SAR), its mechanism of action, resistance studies, model of interaction with the enzyme, etc.


Journal of Medicinal Chemistry | 2009

4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.

Sonia de Castro; Carlos García-Aparicio; Graciela Andrei; Robert Snoeck; Jan Balzarini; María-José Camarasa; Sonsoles Velázquez

We report the synthesis and antiviral activity of a new family of non-nucleoside antivirals, derived from the 4-keto-1,2-oxathiole-2,2-dioxide (beta-keto-gamma-sultone) heterocyclic system. Several 4- and 5-substituted-5H-1,2-oxathiole-2,2-dioxide derivatives were found to have a selective inhibitory activity against human cytomegalovirus (HCMV) and varicella zoster virus (VZV) replication in vitro, being inactive against a variety of other DNA and RNA viruses. A structure-activity relationship (SAR) study showed that the presence of a benzyl at the 5 position and a benzyloxy substituent at the 4 position are a prerequisite for anti-HCMV and VZV activity. The novel compounds do not show cross-resistance against a wide variety of mutant drug-resistant HCMV strains, pointing to a novel mechanism of antiviral action.


Journal of Carbohydrate Chemistry | 2000

Hiv-1 Specific Reverse Transcriptase Inhibitors: why are Tsao-Nucleosides so Unique?

María José Camarasa; Ana San-Félix; Maria Jesus Perez-Perez; Sonsoles Velázquez; Rosa Alvarez; Cristina Chamorro; María Luisa Jimeno; Carlos Pérez; Federico Gago; Erik De Clercq; Jan Balzarini

1. INTRODUCTION AIDS will still be one of the most important challenges for the Scientific Community in the approaching new century. Since the identification, in 1983-84,1,2 of human immunodeficiency virus (HIV) as the etiological agent of AIDS, significant progress has been made in the treatment of HIV-infected patients. This has been in part due to the discovery and clinical use of an increasing number of anti-HIV drugs. However, while highly active antiretroviral therapy (HAART)3 approaches have reduced the morbidity and mortality, the intertwined problems of drug induced viral resistance, poor compliance with complex regimens and therapy failure continue. Therefore, there remains a pressing need for the development of new antiviral agents that can be used not only as first line therapeutic candidates, but also in the antiretroviral-experienced patient population.


Nucleosides, Nucleotides & Nucleic Acids | 1995

TSAO Derivatives: Highly Specific Inhibitors of Human Immunodeficiency Virus Type-1 (HIV-1) Replication

María José Camarasa; Maria J. Péarez-Péarez; Sonsoles Velázquez; Ana San-Féalix; Rosa Alvarez; Simon Ingate; María Luisa Jimeno; Anna Karlsson; Erik De Clercq; Jan Balzarini

Abstract TSAO derivatives represent a unique class of nucleosides that are specifically targeted at HIV-1 RT. This overview is focussed on the chemical synthesis, the conformational studies, the antiviral and metabolic properties of TSAO derivatives, as well as their mechanism of antiviral action and the molecular basis of the rapid selection of resistant HIV-1 strains that emerge in cell culture in the presence of TSAO derivatives.


Journal of Virology | 2001

Exploitation of the Low Fidelity of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase and the Nucleotide Composition Bias in the HIV-1 Genome To Alter the Drug Resistance Development of HIV

Jan Balzarini; María-José Camarasa; María-Jesús Pérez-Pérez; Ana San-Félix; Sonsoles Velázquez; Carlo-Federico Perno; Erik De Clercq; John Anderson; Anna Karlsson

ABSTRACT The RNA genome of the lentivirus human immunodeficiency virus type 1 (HIV-1) is significantly richer in adenine nucleotides than the statistically equal distribution of the four different nucleotides that is expected. This compositional bias may be due to the guanine-to-adenine (G→A) nucleotide hypermutation of the HIV genome, which has been explained by dCTP pool imbalances during reverse transcription. The adenine nucleotide bias together with the poor fidelity of HIV-1 reverse transcriptase markedly enhances the genetic variation of HIV and may be responsible for the rapid emergence of drug-resistant HIV-1 strains. We have now attempted to counteract the normal mutational pattern of HIV-1 in response to anti-HIV-1 drugs by altering the endogenous deoxynucleoside triphosphate pool ratios with antimetabolites in virus-infected cell cultures. We showed that administration of these antimetabolic compounds resulted in an altered drug resistance pattern due to the reversal of the predominant mutational flow of HIV (G→A) to an adenine-to-guanine (A→G) nucleotide pattern in the intact HIV-1-infected lymphocyte cultures. Forcing the virus to change its inherent nucleotide bias may lead to better control of viral drug resistance development.


Oncotarget | 2017

Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.

María Dolores Canela; Sam Noppen; Oskía Bueno; Andrea E. Prota; Katja Bargsten; Gonzalo Sáez-Calvo; María Luisa Jimeno; Mohammed Benkheil; Domenico Ribatti; Sonsoles Velázquez; María José Camarasa; J. Fernando Díaz; Michel O. Steinmetz; Eva María Priego; Maria Jesus Perez-Perez; Sandra Liekens

We investigated the microtubule-destabilizing, vascular-targeting, anti-tumor and anti-metastatic activities of a new series of chalcones, whose prototype compound is (E)-3-(3’’-amino-4’’-methoxyphenyl)-1-(5’-methoxy-3’,4’-methylendioxyphenyl)-2-methylprop-2-en-1-one (TUB091). X-ray crystallography showed that these chalcones bind to the colchicine site of tubulin and therefore prevent the curved-to-straight structural transition of tubulin, which is required for microtubule formation. Accordingly, TUB091 inhibited cancer and endothelial cell growth, induced G2/M phase arrest and apoptosis at 1-10 nM. In addition, TUB091 displayed vascular disrupting effects in vitro and in the chicken chorioallantoic membrane (CAM) assay at low nanomolar concentrations. A water-soluble L-Lys-L-Pro derivative of TUB091 (i.e. TUB099) showed potent antitumor activity in melanoma and breast cancer xenograft models by causing rapid intratumoral vascular shutdown and massive tumor necrosis. TUB099 also displayed anti-metastatic activity similar to that of combretastatin A4-phosphate. Our data indicate that this novel class of chalcones represents interesting lead molecules for the design of vascular disrupting agents (VDAs). Moreover, we provide evidence that our prodrug approach may be valuable for the development of anti-cancer drugs.


Current Pharmaceutical Design | 2006

TSAO Derivatives, Inhibitors of HIV-1 Reverse Transcriptase Dimerization: Recent Progress

M J Camarasa; Sonsoles Velázquez; Ana San-Félix; María-Jesús Pérez-Pérez; M. C. Bonache; S. De Castro

There is an urgent need for the development of new and safer drugs for the treatment of HIV (human immunodeficiency virus) infection, active against the currently resistant viral strains or directed to novel targets in the viral replicative cycle that may be useful for multiple drug combination. TSAO derivatives are a peculiar group of highly functionalized nucleosides that belong to the so-called nonnucleoside RT inhibitors (NNRTIs). HIV-1 reverse transcriptase (RT) is a key enzyme that plays an essential and multifunctional role in the life cycle of the virus and thus represents a key target for antiviral chemotherapeutic intervention. The dimeric form of the enzyme is absolutely required for all enzymatic activities. Thus, the process of dimerization and subsequent maturation into the p66/p51 heterodimer is essential for a fully functional RT and constitutes a target for therapeutic intervention, however to date such agents have not been developed. TSAO molecules are a peculiar group of non-nucleoside RT inhibitors that exert a unique selectivity for HIV-1 through a specific interaction with the p51 subunit of HIV-1 RT. They interact at the p66/p51 heterodimer interface of the enzyme. They were the first small non peptidic molecules shown to interfere with the dimerization process of the enzyme. This review covers the recent work within this family of compounds aimed at enhancing their interaction with the dimer interface of HIV-1 RT.


Tetrahedron | 1994

Synthesis of [1-[3′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-arabino- and β-d-ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T

Sonsoles Velázquez; María-Luisa Jimeno; María-José Camarasa; Jan Balzarini

Abstract Reaction of O -mesylcyanodrins of furanos-2′-ulosyl cytosine with bases afforded β- d -arabino- and ribo-2′-spiro substituted nucleosides. Two of them exist, in solution, as mixtures of rotationally restricted “ syn-anti ” isomers.


Journal of Medicinal Chemistry | 2010

Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.

Alberto Diez-Torrubia; Carlos García-Aparicio; Silvia Cabrera; Ingrid De Meester; Jan Balzarini; María-José Camarasa; Sonsoles Velázquez

Here we explore the applicability of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to a variety of amine-containing drugs. Efficient procedures have been developed for the synthesis of dipeptide and tetrapeptide amide prodrugs including N-acylation protocols of the exocyclic amino function of cytidine and adenosine nucleosides. Our studies demonstrated that XaaPro dipeptides linked to a free amino group present on an aromatic ring or on a sugar entity are prodrugs that efficiently release the parent drug upon conversion by purified DPPIV/CD26 as well as soluble DPPIV/CD26 in bovine and human serum. Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified CD26 but also in human and bovine serum. When the amino group is present on a pyrimidine or purine ring, the dipeptide derivatives are chemically unstable, whereas the tetrapeptide derivatives (i.e., ValProValPro or ValAlaValPro) were much more stable in solution and efficiently converted to the parent drug by the action of DPPIV/CD26. This DPPIV/CD26-directed prodrug technology can be useful to increase solubility of the parent drug molecules and/or to allow better formulation properties.

Collaboration


Dive into the Sonsoles Velázquez's collaboration.

Top Co-Authors

Avatar

Jan Balzarini

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

María-José Camarasa

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Ana San-Félix

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

M J Camarasa

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Erik De Clercq

Rega Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar

María-Jesús Pérez-Pérez

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sonia de Castro

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Esther Lobaton

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

María José Camarasa

Spanish National Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge